1Q23 Business Results

Main Portfolio Remsima Infliximab INFLECTRA EL ME EU US 2013 2016 Truxima Rituximab INFLECTRA 2017 INFL XMAS Product Name Reference Drug Herzuma Trastuzumab 2018 Remsima Infliximab SUBCUTANEOUS 2019 2020 Truxima Rituximab Indications (Herzum (Herzuma Trastuzumab Regkirona 2021 regdanvimab EU Yuflyma adalimumab 2022 Vegzelma bevacizumab Launching Timeline 2023 Vegzelma bevacizumab Yuflyma adalimumab US Remsima Infliximab INFLECTRA NFL MAS RemicadeⓇ (Infliximab) Rheumatoid Arthritis (RA), Ulcerative Colitis (UC), Crohn's disease (CD), etc. Sep 2013 Nov 2016 Truxima Rituximab Ⓡ (Rituximab) Rituxan (MabTheraⓇ) Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), etc. Apr 2017 Nov 2019 (Herzuma® Trastuzumab HerceptinⓇ (Trastuzumab) HER2-Positive Metastatic Breast Cancer, Early Breast Cancer(EBC), etc. May 2018 Mar 2020 Remsima® SUBCUTANEOUS Infliximab (Infliximab) Rheumatoid Arthritis (RA), Ulcerative Colitis (UC), Crohn's disease (CD), etc. Feb 2020 1H24(E) Yuflyma adalimumab HumiraⓇ (Adalimumab) Rheumatoid Arthritis (RA), Ulcerative Colitis (UC), Crohn's disease (CD), etc. Aug 2021 2H23(E) Vegzelma bevacizumab AvastinⓇ (Bevacizumab) Metastatic Colorectal Cancer (MCC), Non-Small Cell Lung Cancer(NSNLC), etc. Oct 2022 Apr 2023 Note: Inflectra TM logo belongs to Pfizer Investor Relations 2023 15 1Q23 Business Results Key Products Plan & Vision Appendix

View entire presentation